C12N 15/8613
Chimaeric vector systems comprising heterologous sequences for production of another viral vector
Official title: {Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
C12N15/8613 (Chimaeric vector systems comprising heterologous sequences for production of another viral vector) appears on 21 US grants and 28 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 28
- Assignees
- 19
- Inventors
- 46
- Latest grant
- 22 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 1 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 3 | 0 |
| 2016 | 0 | 1 |
| 2017 | 2 | 2 |
| 2018 | 1 | 4 |
| 2019 | 2 | 4 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 5 | 3 |
| 2023 | 0 | 2 |
| 2024 | 2 | 1 |
| 2025 | 3 | 3 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Adenoviral vector22 Jul 2025US 12,365,920 B2Oxford University Innovation Limited
- Codon-optimized nucleotide sequences encoding an AP-1 transcription factor8 Apr 2025US 12,270,032 B2Lyell Immunopharma, Inc.
- Compositions and methods for dengue virus chimeric constructions in vaccines7 Jan 2025US 12,186,363 B2Takeda Vaccines, Inc.
- Adenoviral vector30 Apr 2024US 11,970,709 B2Oxford University Innovation Limited
- Compositions and methods for dengue virus chimeric constructions in vaccines19 Mar 2024US 11,931,399 B2Takeda Vaccines, Inc.
- Adenoviral helper plasmid16 Jul 2026US 2026/0201418 A1Forge Biologics, Inc.
- Bispecific checkpoint inhibitor antibodies30 Oct 2025US 2025/0333519 A1Xencor, Inc.
- Codon-optimized nucleotide sequences encoding an ap-1 transcription factor25 Sep 2025US 2025/0297268 A1Lyell Immunopharma, Inc.
- Compositions and Methods for Dengue Virus Chimeric Constructions in Vaccines16 Jan 2025US 2025/0018006 A1Takeda Vaccines, Inc.
- Adenoviral Vector12 Sep 2024US 2024/0301443 A1Oxford University Innovation Limited
Most cited
By later US patents
- Bispecific checkpoint inhibitor antibodies11US 10,787,518 B2Xencor, Inc. · 2020
- Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer8US 9,163,261 B22015
- Chimeric adenoviral vectors3US 7,879,602 B2Vaxart, Inc. · 2011
- Compositions and methods for dengue virus chimeric constructs in vaccines2US 9,783,579 B2Takeda Vaccines, Inc. · 2017
- Vector comprising multiple homologous nucleotide sequences1US 10,072,274 B2Bavarian Nordic A/S · 2018